List of Excipients in Branded Drug GLUCOPHAGE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bristol-Myers Squibb Company	GLUCOPHAGE	metformin hydrochloride	0087-6060	HYPROMELLOSES
Bristol-Myers Squibb Company	GLUCOPHAGE	metformin hydrochloride	0087-6060	MAGNESIUM STEARATE
Bristol-Myers Squibb Company	GLUCOPHAGE	metformin hydrochloride	0087-6060	POVIDONE

GLUCOPHAGE Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: October 5, 2026

Glucophage is the immediate-release brand of metformin hydrochloride, while Glucophage XR is the extended-release version. The active ingredient is off-patent and widely genericized. Commercial value therefore resides less in the metformin molecule and more in excipient selection, release control, tolerability, manufacturing efficiency, regulatory differentiation, and patient adherence.

The strongest opportunities are once-daily extended-release tablets, lower-gastrointestinal-burden formulations, fixed-dose combinations, multiparticulate delivery systems, and products designed for patients with swallowing or adherence limitations. New excipient patents can support market position, but basic metformin tablets face limited freedom-to-operate barriers because the drug, conventional tablet technologies, and common excipients are mature.

What is Glucophage and which formulations use excipients strategically?

Glucophage contains metformin hydrochloride, a biguanide antihyperglycemic agent used primarily for type 2 diabetes. Glucophage XR uses a controlled-release tablet designed to reduce dosing frequency and improve gastrointestinal tolerability relative to immediate-release metformin.[1,2]

Product	Dosage form	Typical dosing concept	Excipient strategy
Glucophage	Immediate-release film-coated tablet	Usually divided daily dosing	Rapid disintegration, compression, film coating, low-cost manufacture
Glucophage XR	Extended-release tablet	Once-daily or less frequent administration	Hydrophilic polymer matrix, controlled hydration, diffusion and erosion control
Generic metformin IR	Immediate-release tablet or oral solution	Divided daily dosing	Cost, manufacturability, bioequivalence
Generic metformin ER	Extended-release tablet	Once-daily dosing	Release profile, dissolution robustness, tablet size, gastrointestinal tolerability
Combination products	Fixed-dose tablets	Metformin plus another antidiabetic	Bilayer or multilayer design, chemical compatibility, dose flexibility

The active pharmaceutical ingredient is highly water soluble. That characteristic simplifies dissolution but creates formulation challenges for extended release. The formulator must prevent rapid drug dumping while maintaining a reproducible release profile across food conditions, gastrointestinal pH, tablet hardness, and manufacturing scale.

What excipients are used in Glucophage and Glucophage XR?

The FDA-approved labeling identifies conventional tablet excipients, including polymers, lubricants, and coating materials. Exact excipient composition can vary by strength, market, manufacturing site, and product version. The current prescribing information and DailyMed labeling should control any product-specific assessment.[1,2]

Glucophage immediate-release excipient profile

Immediate-release metformin tablets generally use:

• Povidone or another binder to improve granule and tablet integrity.
• Magnesium stearate as a lubricant.
• Hypromellose and other film-coating components for appearance, handling, and protection.
• Pigments or opacifiers where required for product identification.

The immediate-release formulation does not require a sophisticated release-controlling matrix. Its commercial objective is reliable disintegration and dissolution at low cost. Excipients must support high-dose tablet compression because metformin hydrochloride has a high dose-to-tablet-mass ratio.

Glucophage XR excipient profile

Extended-release metformin depends on hydrophilic matrix technology. Hypromellose and related cellulose polymers can hydrate after ingestion, forming a gel layer that controls water penetration and metformin diffusion. Povidone, cellulose derivatives, lubricants, and coating materials may support granulation, matrix integrity, and processability.

The main formulation variables include:

1. Polymer grade and viscosity.
2. Polymer concentration.
3. Drug-to-polymer ratio.
4. Granule size and porosity.
5. Compression force and tablet hardness.
6. Coating permeability.
7. Tablet dimensions and surface area.
8. Dissolution performance under fed and fasted conditions.

XR formulations must also manage the “ghost tablet” phenomenon. Insoluble or slowly eroding matrix remnants may appear in stool after drug release. This can alarm patients even when the product performs as intended. Labeling and patient counseling are important commercial and adherence considerations.[2]

How does excipient selection affect metformin product performance?

Excipient selection determines whether a metformin product can satisfy dissolution, bioequivalence, stability, and manufacturing requirements.

Release control

Hydrophilic polymers are the central release-control excipients for metformin ER. Higher-viscosity polymers and greater polymer loading generally slow drug release, although the relationship is nonlinear. Excessive polymer content can produce an oversized tablet or incomplete drug release. Insufficient polymer content can cause an early burst.

A commercial formulation should target a release profile that is robust rather than merely optimized under one dissolution method. Changes in polymer supplier, particle size, substitution level, or moisture content can materially change release behavior.

Gastrointestinal tolerability

Metformin commonly causes nausea, diarrhea, abdominal discomfort, and flatulence. Excipients cannot eliminate all active-ingredient-related gastrointestinal effects, but release control can reduce peak exposure and local intestinal concentration. This is the commercial rationale for ER formulations.

Potential strategies include:

• Smoother release over 12 to 24 hours.
• Reduced initial drug burst.
• Lower tablet erosion rate.
• Delayed or site-specific release.
• Lower-dose combination products that preserve metformin exposure while improving adherence.

These claims require clinical or comparative evidence. A formulation patent alone does not establish superior tolerability.

Tablet size and swallowability

Metformin doses are large. A high-dose XR tablet can be difficult to swallow, particularly for older adults and patients with dysphagia. Excipients that improve compactibility can reduce tablet volume, but higher compression may alter porosity and release. Direct compression is attractive for cost and simplicity, yet wet granulation may provide better content uniformity and tablet strength at high drug loading.

Commercial opportunities include:

• Smaller high-dose tablets.
• Multi-unit-dose regimens using lower-strength tablets.
• Sprinkleable multiparticulates.
• Oral granules.
• Liquid or suspension products.
• Orally disintegrating products, where dose loading permits.

Each option must balance palatability, dose accuracy, stability, and regulatory feasibility.

Stability and moisture control

Metformin hydrochloride is generally stable, but excipient moisture, tablet porosity, and packaging can affect long-term performance. Hydrophilic polymers may absorb moisture and change release kinetics. Blister packaging or high-barrier bottles can reduce risk, particularly in hot and humid markets.

Manufacturers should characterize:

• Water activity.
• Polymer moisture uptake.
• Tablet hardness after storage.
• Dissolution after accelerated aging.
• Packaging interaction.
• Extractables and leachables for specialized delivery systems.

What formulation patents protect metformin products?

The basic metformin molecule and conventional immediate-release tablet technology are no longer meaningful exclusivity barriers in the United States. Patent value is concentrated in specific delivery systems, combinations, manufacturing processes, and device-linked formulations.

Protection category	Commercial relevance	Likely durability
Metformin compound patents	Historical protection only	Expired
Conventional IR tablets	Low barrier because technology is routine	Weak
Hydrophilic ER matrix	Can support formulation claims if technically narrow	Moderate to weak against design-around
Multiparticulate or delayed-release systems	Potentially stronger if clinically differentiated	Moderate
Fixed-dose combinations	May include formulation and method claims	Product-specific
Manufacturing processes	Useful where process produces a measurable product attribute	Variable
Abuse-deterrent or specialized delivery	Potential niche protection	Depends on evidence and claim scope
Pediatric, liquid, or sprinkle formulations	Can create commercial differentiation	Usually limited patent strength

A patent claiming only “metformin and a sustained-release polymer” faces substantial prior-art and design-around risk. Stronger claims typically require a defined polymer system, dissolution profile, particle architecture, tablet geometry, manufacturing condition, or clinically relevant performance result.

What is the Orange Book status of Glucophage?

Glucophage and Glucophage XR are legacy FDA-approved products with extensive generic competition. The active ingredient is not protected by current compound exclusivity. FDA Orange Book records should be checked for the current listing of each NDA and any remaining patent or exclusivity entry.[3]

Regulatory issue	Glucophage assessment
Active ingredient	Metformin hydrochloride
FDA pathway	NDA for branded products; ANDA for most generic tablets
New chemical entity exclusivity	Expired
Compound patent barrier	Expired
Current generic competition	Extensive
Biosimilar pathway	Not applicable
Core commercial barrier	Formulation quality, supply, price, and distribution
Orange Book relevance	Product-specific listed patents, if any, must be confirmed in the current edition

Glucophage XR generic entry has historically involved formulation-specific regulatory work because an applicant must demonstrate comparable release behavior and bioequivalence. That regulatory burden is meaningful, but it does not create the same protection as an active patent.

When did Glucophage lose exclusivity and when can generic metformin enter?

Generic metformin has been available for many years. The original compound and early branded-product exclusivity periods expired long ago. Generic launch is therefore legally possible, subject to FDA approval and any product-specific patent certification.

For a new metformin ER product, the relevant exclusivity may arise from:

• A new formulation patent.
• A new combination product.
• A new route of administration.
• Pediatric exclusivity.
• Orphan-drug exclusivity, if an eligible rare-disease indication existed.
• Three-year clinical-investigation exclusivity for a qualifying change.
• Five-year new chemical entity exclusivity, which does not apply to ordinary reformulations of metformin.

A formulation developer should not assume that an approved reformulation receives five-year exclusivity. FDA exclusivity depends on the statutory basis of the application and the type of innovation.[4]

What Paragraph IV challenges and patent litigation affect Glucophage?

Metformin IR and ER are mature generic markets. Paragraph IV activity has historically focused on specific branded ER products and formulation patents rather than the metformin compound itself. The business impact of any Paragraph IV challenge depends on the patent listed for the reference product, the ANDA’s certification, the timing of litigation, and whether a 30-month stay applies under the Hatch-Waxman framework.[5]

For a current transaction or launch plan, the relevant analysis is:

1. Identify the reference listed drug and NDA.
2. Review the current Orange Book patent listing.
3. Determine whether the applicant filed Paragraph I, II, III, or IV certifications.
4. Assess whether the patent owner filed suit within 45 days.
5. Review any settlement, license, or launch date.
6. Compare the proposed product with active claims, including formulation and dissolution limitations.

No biosimilar litigation applies because metformin is a small-molecule drug, not a biologic. The relevant competitive pathway is the ANDA process, not the abbreviated pathway under the Public Health Service Act.

Which excipient strategies offer the strongest commercial opportunities?

1. Improved extended-release metformin

The largest opportunity is a once-daily ER product with a smaller tablet and a more consistent release profile. The product must show a practical benefit over existing generic ER tablets, such as improved swallowability, lower variability, reduced gastrointestinal discontinuation, or simpler dosing.

A new formulation should avoid relying on polymer substitution alone. The commercial case is stronger when the formulation delivers a measurable patient or manufacturing benefit.

2. High-dose, low-volume tablets

Reducing tablet size is difficult because metformin doses are large. The most promising approaches include:

• Higher compactibility excipients.
• Co-processed excipients.
• Granule engineering.
• Improved API particle engineering.
• Bilayer or multilayer tablets.
• Lower-density matrix systems with equivalent release control.

The principal risks are capping, sticking, weight variation, and dissolution drift during scale-up.

3. Sprinkleable or multiparticulate products

Multiparticulates can improve administration for patients unable to swallow tablets. Drug-loaded pellets or mini-tablets may be placed in capsules, sachets, or suitable food vehicles. The formulation must prevent dose segregation, rapid release after crushing or chewing, and unacceptable taste.

This segment may support pediatric, geriatric, institutional, and adherence-focused positioning. Regulatory requirements are higher than for a simple generic tablet because administration instructions and food compatibility must be demonstrated.

4. Oral liquid and powder products

Liquid metformin products can address dysphagia and pediatric use. The main excipient challenges are taste masking, chemical stability, preservative selection, viscosity, sedimentation, and dose-measurement accuracy.

Potential excipients include sweeteners, flavors, suspending agents, buffers, preservatives, and viscosity modifiers. Taste masking is central because metformin has a strong, unpleasant taste. A ready-to-use liquid may have meaningful supply-chain disadvantages because of shipping weight and stability requirements. A reconstitutable powder can reduce those costs but adds dispensing and reconstitution risks.

5. Fixed-dose combinations

Metformin is commonly combined with DPP-4 inhibitors, SGLT2 inhibitors, sulfonylureas, thiazolidinediones, and other antidiabetic agents. Combination products create excipient and manufacturing challenges involving:

• Different dose ratios.
• Different release rates.
• Chemical incompatibility.
• Bilayer compression.
• Separate granulation conditions.
• Stability of multiple APIs.
• Dose titration limitations.

A bilayer or sequential-release product can provide stronger differentiation than a conventional single-layer tablet. Patentability depends on the specific architecture and demonstrated performance.

6. Manufacturing-cost reduction

For a mature generic, cost leadership can be more valuable than marginal pharmacokinetic differentiation. Opportunities include:

• Direct compression where feasible.
• Fewer granulation steps.
• Lower-cost polymer grades with equivalent performance.
• Continuous manufacturing.
• Reduced coating weight.
• High-speed compression with less tooling wear.
• Improved yield and lower reject rates.
• Localized excipient supply.

The strongest manufacturing patents claim a reproducible process tied to a measurable product attribute, such as dissolution, hardness, porosity, or content uniformity. Process claims that lack a distinctive product result may be easier to challenge or circumvent.

How does Glucophage compare with other metformin products?

Attribute	Glucophage IR	Glucophage XR	Generic metformin IR	Generic metformin ER	Next-generation opportunity
Dosing frequency	Usually multiple daily doses	Usually once daily	Multiple daily doses	Usually once daily	Once daily or patient-specific
Excipient complexity	Low	Moderate to high	Low	Moderate to high	High
Patent barrier	Minimal	Product-specific historical claims	Minimal	Product-specific claims	Depends on formulation
Main differentiation	Brand recognition	Extended release	Price and availability	Price and release profile	Tolerability, size, adherence
Manufacturing risk	Low	Dissolution and scale-up	Low	Moderate	Moderate to high
Commercial margin	Low to moderate	Low to moderate	Low	Low to moderate	Potentially higher if clinically differentiated

Glucophage retains brand recognition in some markets, but generic substitution and price competition limit brand-based pricing. A new product needs a clear advantage in adherence, tolerability, administration, or cost.

What geographic opportunities exist for Glucophage excipient innovation?

The United States is a mature, price-sensitive market with extensive generic competition. Growth opportunities are more likely in:

• Emerging markets with rising type 2 diabetes prevalence.
• Markets where branded generics retain commercial value.
• Regions with limited access to high-quality ER metformin.
• Institutional channels requiring simplified dosing.
• Pediatric and geriatric segments.
• Countries with hot and humid storage conditions.
• Markets where dysphagia-friendly products are underdeveloped.

Geographic patent protection should focus on jurisdictions where the formulation can obtain meaningful market share. A global filing strategy for a minor polymer variation may not justify its cost. Priority should go to claims covering the product’s highest-value technical feature, then to markets with credible enforcement and reimbursement access.

What generic launch risks exist for a new Glucophage formulation?

The major risks are regulatory rather than molecule-level patent risks.

Risk	Impact	Mitigation
Failure to match dissolution	ANDA or hybrid application delay	Design robust release profile across media and batches
Tablet too large	Poor adherence and lower substitution	Optimize dose loading and polymer content
Food-effect variability	Labeling restrictions or clinical failure	Conduct fed and fasted studies early
Polymer supply variation	Batch-to-batch release drift	Qualify multiple suppliers and define critical material attributes
Infringement of formulation claims	Litigation or launch delay	Claim mapping and design-around analysis
Taste or swallowing failure	Low uptake	Patient-centered administration testing
Manufacturing yield loss	Margin compression	Scale-up before pivotal stability lots
Price erosion	Limited return on development cost	Target differentiated channels or combinations
Labeling confusion	Discontinuation or medication errors	Clear instructions for XR use and tablet integrity

How strong is the patent estate for Glucophage?

The core patent estate is weak because metformin is an old, genericized active ingredient and conventional tablets are routine. The remaining value lies in narrow formulation, combination, delivery, and manufacturing claims.

Patent strength is highest when claims include:

• A defined release profile linked to a test method.
• A specific polymer architecture.
• A distinctive multiparticulate structure.
• A measurable reduction in tablet size or dose burden.
• A clinically demonstrated tolerability or pharmacokinetic result.
• A manufacturing process that produces a non-obvious product property.

Patent strength is lower when claims cover:

• Metformin combined with a generic hydrophilic polymer.
• Broad lists of conventional excipients.
• Routine coating or lubrication steps.
• Functional language without reproducible testing parameters.
• Formulations that can be readily reproduced with common excipient substitutions.

Key Takeaways

• Glucophage is an immediate-release metformin product; Glucophage XR is the extended-release version.
• Metformin compound exclusivity has expired, and generic competition is extensive.
• Excipient value is concentrated in release control, tablet size, gastrointestinal tolerability, stability, and manufacturability.
• Hydrophilic polymer matrices are the central technology for metformin ER products.
• The strongest commercial opportunities are smaller once-daily tablets, sprinkleable multiparticulates, oral liquids, fixed-dose combinations, and lower-cost manufacturing.
• Biosimilar risk is irrelevant because metformin is a small-molecule drug.
• Current Orange Book records and product-specific patent claims must be reviewed before launch or licensing decisions.
• A new product needs a measurable clinical, administration, or cost advantage to overcome generic price erosion.

FAQs

Can excipients create new patent protection for metformin?

Yes. A patent can protect a specific excipient system, polymer architecture, release profile, particle structure, manufacturing process, or combination formulation. The claims must be novel and non-obvious over existing metformin and controlled-release prior art.

Is hypromellose sufficient to create a patentable Glucophage XR substitute?

Usually not by itself. Hypromellose is a widely used controlled-release polymer. Patentability generally requires a specific grade, concentration, combination, process, geometry, dissolution profile, or demonstrated technical effect.

Are metformin extended-release tablets eligible for biosimilar competition?

No. Metformin is a chemically synthesized small-molecule drug. Competition proceeds primarily through FDA abbreviated new drug applications, not biosimilar applications.

What is the most attractive excipient opportunity for a generic metformin manufacturer?

A robust once-daily formulation that reduces tablet size, improves gastrointestinal tolerability, and maintains bioequivalence offers the clearest opportunity. Manufacturing-cost reduction is equally important in highly commoditized markets.

Can a liquid metformin product obtain market exclusivity?

A liquid or reconstitutable formulation may obtain formulation patents or regulatory exclusivity in limited circumstances, but ordinary reformulation does not automatically receive new chemical entity exclusivity. Commercial protection depends on the specific innovation, approval pathway, patent claims, and market differentiation.

References

1. U.S. Food and Drug Administration. (2023). Glucophage (metformin hydrochloride) tablets: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Glucophage XR (metformin hydrochloride extended-release tablets): Prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Small business assistance: Frequently asked questions on the abbreviated new drug application process. FDA.

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.